Altogether, this work identifies a new antagonist interplay between CBX3 and IFNγ signaling to regulate colon immune response and chemosensitivity of colorectal cancer, which highlights CBX3 as a potential target to improve the treatment of UC and colorectal cancer. This evidence concerns the gene IFNG and colorectal cancer.